CJ Regenerative Medical Technology Co.,Ltd., United States
Abstract: PRP (Platelet-Rich Plasma) refers to a procedure that involves collecting a patient’s blood, followed by centrifugation to obtain plasma with a platelet concentration 4-5 times higher than that of normal blood. The biological advantages of PRP include its autologous origin, which reduces the risk of immune reactions or side effects, an increased release of growth factors due to concentrated platelets, and superior biocompatibility compared to synthetic materials by mimicking natural healing processes. However, PRP has limitations: most growth factors are released within 10 minutes to 24 hours after injection, resulting in a short duration of effect; the use of anticoagulants (e.g., EDTA) can cause pH mismatches leading to growth factor loss; and efficacy varies depending on the patient’s platelet condition. These drawbacks highlight the need to optimize PRP’s therapeutic potential. Additionally, previous studies suggest that PRF (Platelet-Rich Fibrin) extends growth factor release through a fibrin matrix but may lack sufficient initial concentration.To address this, this study aimed to select an appropriate anticoagulant, adjust its concentration and centrifuge speed, extract fibrin fibers from PRF, and combine them with PRP’s growth factors to enhance the duration and concentration of growth factor activity. The goal was to develop a method that achieves an optimal concentration for a relatively simple injectable procedure. Due to experimental constraints, direct experimentation was not feasible; instead, results were predicted by comparing and analyzing existing literature and validated through empirical patient cases. Theoretical considerations were discussed with various researchers and clinicians to refine the approach.
This study confirmed that the proposed method could be broadly applied to burn treatment, scar therapy, and skin aesthetics.
